When Al Robichaud got his start as a medicinal chemist in 1991, he knew that discovering and developing drugs meant shouldering some level of risk. But around 2011, it became clear that the process for developing brain drugs was too costly and risky for major pharmaceutical companies to justify pursuing, as companies including Novartis (NYSE:NVS), GlaxoSmithKline (NYSE:GSK), […]
Senseonics closes $150m public offering
Senseonics (NYSE:SENS) said today that it closed an underwritten public offering of its common stock, reeling in $149.5 million in total proceeds. The Germantown, Md.-based company plans to use its newly-acquired funds to support the commercialization of its implantable continuous glucose monitoring system, Eversense. “We are pleased with the results of this transaction and the […]
Medtronic launches outcomes-based reimbursement program for MiniMed 670G system
Medtronic (NYSE:MDT) today launched an outcomes-based reimbursement program for its MiniMed 670G automated insulin delivery system. As part of its ‘MiniMed 670G Performance Guarantee Program,’ the medtech giant will dole out flat-fee reimbursements of up to $25,000 per pump over four years for diabetes-related inpatient hospitalization and ER admissions. Medtronic said the program offers the company […]
Study: Heat-stable drug formulation offers new option to prevent postpartum bleeding
Data from a collaboration between Ferring Pharmaceuticals, Merck (NYSE:MRK) and the World Health Organization showed that a heat-stable formulation of carbetocin is as effective as oxytocin for the prevention of excessive bleeding following vaginal birth. Millions of women are affected by postpartum hemorrhage every year, according to Ferring Pharmaceuticals. Traditionally, women are given oxytocin to prevent […]
Eli Lilly touts data for concentrated insulin delivered via Insulet’s Omnipod tech
Eli Lilly (NYSE:LLY) touted data this week from a Phase III study evaluating its Humulin R U-500 concentrated insulin delivered via Insulet‘s (NSDQ:PODD) investigational Omnipod U-500 device. The company reported that people with Type II diabetes taking Humulin R U-500 using the Omnipod device experienced greater A1c reductions and needed less daily insulin compared to adults […]
Medtronic, IBM Watson Health launch AI-powered diabetes management app
Medtronic (NYSE:MDT), in partnership with IBM Watson Health, this week announced commercial availability of its AI-powered Sugar.IQ diabetes management app. Using artificial intelligence, the Sugar.IQ app evaluates how a user’s blood sugar levels respond to variables such as food intake, insulin dosing and other daily routines. At this year’s meeting of the American Diabetes Association, Medtronic […]
Sensile Medical partners with Verily, Sanofi to develop connected insulin patch pump
Swiss medical device-maker Sensile Medical announced this week that it struck a deal with Verily and Sanofi (NYSE:SNY) to develop and commercialize a connected insulin patch pump. The pre-filled insulin patch pump will be designed primarily for people with Type II diabetes, according to the Olten, Switzerland-based company. Each company brings its own unique strength to […]
One Drop launches blood glucose prediction, decision support features
One Drop this week launched blood glucose prediction and automated decision support features for its mobile app designed to help people manage their diabetes. The company said that the new features will enable its mobile app to give blood glucose predictions up to 12 hours into the future and behavioral recommendations based on those forecasts. […]
Enteris BioPharma touts more Phase II data for oral endometriosis therapy
Enteris BioPharma this week touted positive results from the final treatment arm of a Phase IIa trial of Ovarest, the company’s oral formulation of leuprolide. The drug is designed as an alternative to the injectable therapies available for people with endometriosis. Data from the last treatment arm of Enteris’ Phase IIa trial showed that the optimized […]
Senseonics prices $130m public offering
On the heels of an FDA approval for its implantable continuous glucose monitoring tech, Senseonics‘ (NYSE:SENS) today priced a $130 million underwritten public offering of common stock. The offering, which is slated to close on June 28, also includes a 30-day option for underwriters to buy additional shares of common stock worth up to $19.5 […]
